Psychopharmacology Of Neurologic Disease

Psychopharmacology of Neurologic Disease, Volume 165 in the Handbook of Clinical Neurology series, provides clinicians with an up-to-date, critical review of the best approaches to treatment of neurologic disease as discussed by experienced clinical investigators. The book is organized into sections on dementia, delirium, movement disorders, hereditary degenerative disease, epilepsy and psychogenic seizures, brain vascular disease, pseudobulbar affect, traumatic brain injury, neuro-oncology, multiple sclerosis and other demyelinating disorders, chronic fatigue syndrome/fibromyalgia, pain, headache, sleep disorders, autoimmune encephalitis/anti- NMDA encephalitis, functional sensory neurologic symptom disorders and neurodevelopmental disorders. Each of these diagnostic categories has a significant incidence of behavioral symptomatology that is secondary to the neurologic diagnosis that can serve to complicate other therapeutic interventions, alter the course of illness, and cause distress in patients and family caregivers. Provides a systematic, evidence-based compendium of best practices in the treatment of behavioral symptomatology relating to neurologic conditions Integrates state-of-the-art approaches in treating all behavioral symptomatology across all major neurologic disorders Explores psychopharmacological intervention, non-pharmacological strategies, behavioral symptomatology, and therapeutic interventions

This book provides neurologists with a basic knowledge of psychiatric medications. It begins with general principles of psychopharmacology and the frequency of psychiatric illness in neurology patients. It goes on to cover psychoactive drugs in the elderly and treating behavioral symptoms of dementia. There is a special emphasis on drug-drug and drug-diet interactions that may be seen in clinical practice. Neurologists, residents, neuropsychiatrists, neuropsychologists and psychiatrists in training will find this practical guide invaluable in numerous clinical settings.

A guide that assists diagnosis and therapeutic of neurological and psychiatric disorders. It includes an introductory chapter that covers basic neuroscience and pharmacology as they pertain to the treatment of central nervous system disorders.

"Psychopharmacology of the Aging Nervous System" was selected as the topic for Volume 20 of the Handbook of PsychopharmacoloffY. Senile dementia is now widely recognized as a medical and social problem likely to reach epidemic proportions by the turn of the century. By that time it is esti mated that almost 20% of the population in most developed countries will be over the age of 65 and at a conservative estimate 1 in 10 of them will suffer from a dementing illness. Many symposia have appeared over the last few years describing the neuropathological and neurochemical deficiencies in Alzheimer's and other forms of dementia, the neuropsychological features of the disease, and attempts to treat it. In this volume, we have selected topics and authors who are beginning to question some of the earlier assumptions and to ask different questions about dementia. In the first four chapters the neuropathology and neu rochemistry of dementia are reevaluated. It is important to understand the relationship between the formation of amyloid plaques and neurofibrillary tangles, the progressive degeneration in cortex, and the neurochemical deafferentation of cortex. In particular, the possibility is considered that the most severe pathology is seen in a well-defined limbo/cortical circuitry known to be involved in mnemonic processing. The growing interest in the genetic determinants of familial Alz heimer's is reviewed. It is also recognized that detailed comparisons of the neural and psychological characteristics of the various degenerative dis eases that impair cognitive processing may be valuable.

Neuropsychiatry and Behavioral Pharmacology explores the neuropsychiatric consequences of congenital and acquired brain lesions and their appropriate pharmacologic treatment. The clinical problems addressed - practically, though always in a theoretical framework - are the severe behavioral disorders of children, of retarded people, of people with epilepsy, and of victims of traumatic brain injury. Topics examined include the neuropsychiatric and delayed neurobehavioral sequelae of traumatic brain injury, inadvertent drug effects, self-injurious behavior, Cornelia De Lange syndrome, autism, tardive dyskinesia, and childhood hyperactivity.

An essential update of clinical trials in the management of neurological and neuropsychiatric disorders.

The landmark description by Delay and Deniker in 1952 of chlorpromazine's effect in psychosis suddenly eclipsed all other progress in psychopharmacology over the previous centuries. Since this report 35 years ago, a vast amount of research has contributed to the major advances in treatment that have improved the lives of millions of patients who would otherwise be incapacitated by their psychiatric disorders. This research has also led to valuable new insights into the causes of mental illnesses and the mechanisms of action of therapeutic drugs. However, there is much more work to be done. Thus, it is of great value periodically to assess the present state of knowledge as a first step to charting future directions. This symposium held in Denmark in 1987 covered many critical issues in psychopharmacology. The etiology, pathogenetic mechanisms, clinical aspects, and future directions of research in schizophrenia, affective disorders, anxiety, and dementia are addressed. Several of the problems with current therapeutic agents, such as side effects and limited efficacy, are also reviewed. Preclinical strategies with existing and new animal and computer models are discussed to point the way for developing better psychopharmacologic treatments of all psychiatric disorders.